Cellix fixes ?800,000 for R&D
Thursday February 15 2007
CELLIX Limited, a developer of technology platforms for the drug discovery industry, has completed an ?800,000 investment round.
CELLIX Limited, a developer of technology platforms for the drug discovery and diagnostics industries, has announced the completion of an ?800,000 investment round in the company.
It was formed as a spin-out from research completed in Trinity College Dublin.
NCB Ventures, the venture capital arm of NCB Group, led the investment.
Co-investors were OTC, a French Venture Capital fund and Enterprise Ireland.
The seed capital raised will be used to finance the company's continued R&D as well as expansion into international markets.
At the announcement were Michael Murphy, chief executive of NCB Ventures with Vivienne Williams, managing director of Cellix.
